Nasdaq exas.

Feb 21, 2023 · Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ... Fintel reports that on May 10, 2023, Credit Suisse maintained coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24 ...Nasdaq: EXAS · Russell 1000 component. Industry, Molecular diagnostics. Founded, 1995; 28 years ago (1995) in Marlborough, Massachusetts. Founders. Stanley ...Source: Third-quarter 2023 earnings slides. Currently, EXAS projects its 2023 revenue to be between $2.48 billion and $2.49 billion. Yet, at its current growth pace, my calculations suggest a more ...

The average one-year price target for EXAS / Exact Sciences Corp. is $112.948. The forecasts range from a low of $85.85 to a high of $136.5. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to ...Posted by Defense World Staff on Nov 1st, 2023. Exact Sciences Co. ( NASDAQ:EXAS – Get Free Report) saw a large growth in short interest during the month of October. As of October 15th, there ...TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.

Nov 30, 2023 · Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is ...

3 Nov 2023 ... Exact Sciences Corporation [EXAS] Rings the Nasdaq Closing Bell | LIVE 07:29 Nasdaq MarketSite 3n #2.91% ЕХАСТ SCIENCES MAtaria Mvesday ...Exact Sciences' CEO is Kevin Conroy, appointed in Apr 2009, has a tenure of 14.58 years. total yearly compensation is $14.22M, comprised of 3.6% salary and 96.4% bonuses, including company stock and options. directly owns 0.68% of …Oct 9, 2023 · MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its ... These dynamics opened the door for Exact Sciences (NASDAQ:EXAS) to serve a rapidly expanding subsector of the healthcare industry by developing and commercializing novel molecular diagnostic tests ...

Turning to the calls side of the option chain, the call contract at the $60.00 strike price has a current bid of $4.20. If an investor was to purchase shares of EXAS stock at the current price ...

The company is scheduled to release Q3 earnings on November 3, 2022, after the market close. The market expects revenue of $503 million, a modest 10% YoY growth forecast. As EXAS starts shifting ...

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted).As of today (2023-11-13), Exact Sciences's share price is $59.44.Exact Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.59.Therefore, Exact Sciences's …One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38.05% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...1 Mar 2017 ... Exact sciences rings the Nasdaq Closing Bell! $EXAS #CRCcountdown.EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...

Exact Sciences Corp (NASDAQ:EXAS) Intrinsic Valuation. Check if EXAS is overvalued or undervalued under the bear, base, and bull scenarios of the company's ...Exact Sciences Corporation EXAS is set to report second-quarter 2022 results on Aug 2, after the closing bell. In the last reported quarter, the company reported a net loss of $1.04, which was ...A Look At The Intrinsic Value Of Exact Sciences Corporation (NASDAQ:EXAS) (Simply Wall St.) Jul-10-23 08:21AM Top 5 Non-Tech Nasdaq Winners of 1H With More Upside Left (Zacks) 06:00AM Exact Sciences schedules second quarter 2023 earnings call (PR Newswire) Jul-04-23 10:40AM ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Webull offers EXAS Ent Holdg (EXAS) historical stock prices, in-depth market analysis, NASDAQ: EXAS real-time stock quote data, in-depth charts, free EXAS options chain data, and a fully built financial calendar to help you invest smart. Buy EXAS stock at Webull.Exact Sciences world-class team is the driving force behind the most innovative growth engine in cancer diagnostics. Our scientists are using advanced technologies to harness the power of DNA, RNA ...Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ...

Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001.

Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...On May 17, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $78.63 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was 18.54%, and its shares gained 45.61% of ...According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.In the past 30 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has remained constant at $1.90 per share. The Zacks Consensus Estimate for 2023 revenues is pegged at $2.46 ...Fintel reports that on May 5, 2023, UBS initiated coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 18.36% Upside. As of April 24, 2023, the ...127.60%. Get the latest Exact Sciences Corp (EXAS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.Exact Sciences' stock was down by 11.2% on sky-high volume as of 3:30 p.m. ET Wednesday afternoon. Although 2023 Q2 revenue jumped 19% year over year to $622 million, Wall Street apparently wanted ...1. Exact Sciences. Exact Sciences' goal is to eradicate cancer. Perhaps that's too optimistic, but the company could play a role in reducing cancer deaths through its diagnostic solutions.

Exact Sciences Corporation Common Stock (EXAS) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.

EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.

EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. 67.03 USD R +3.03 +4.73%. At close at Dec 1, 16:58 UTC-8. USD. No trades. See on …WebAccording to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.Exact Sciences Corp (EXAS) latest news, insider trading and hedge fund ownership data provided by Insider Monkey. ... Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript.Who is on Exact Sciences's Insider Roster? The list of insiders at Exact Sciences includes Brian Baranick, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, and Sarah Condella. Learn more on insiders at EXAS.This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%.EXAS earnings call for the period ending March 31, 2023. Image source: The Motley Fool. Exact Sciences ( EXAS 0.14% ) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ETThe company is scheduled to release Q3 earnings on November 3, 2022, after the market close. The market expects revenue of $503 million, a modest 10% YoY growth forecast. As EXAS starts shifting ...Exact Sciences Co. (NASDAQ:EXAS – Free Report) – Analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Exact Sciences in a research report issued to clients and investors on ...View Our Latest Research Report on EXAS. Exact Sciences Price Performance. Shares of NASDAQ EXAS opened at $67.29 on Tuesday. The stock has a market capitalization of $12.17 billion, a price-to ...Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. ... To EXAS's credit, this debt issuance has been opportunistic CV offerings, at ...

Formed in 1995, Exact Sciences ( NASDAQ: EXAS) is a cancer screening and diagnostics company with the aim of early detection and improving cancer treatment. Currently, the company caters to ...Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewha... Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last qu...3 Nov 2023 ... Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, visits the Nasdaq MarketSite in Times Square.Instagram:https://instagram. best budget internetnasdaq mcomchip etf stocknyse gwh Exact Sciences Stock Price, News & Analysis (NASDAQ:EXAS) $67.03 +3.03 (+4.73%) (As of 12/1/2023 ET) Compare Today's Range $62.76 $67.03 50-Day Range …Web best llc online servicegle amg 63s Oct 13, 2022 01:52PM EDT. Investors in EXACT Sciences Corp. (Symbol: EXAS) saw new options begin trading today, for the December 2nd expiration. At Stock Options Channel, our YieldBoost formula ... synthetic biology companies EXASNASDAQ See on Supercharts Overview News Ideas Financials Technicals Forecast EXAS chart Today 4.73% 5 days 2.38% 1 month 9.53% 6 months −21.08% Year to date …WebIf you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...